In March 2015, Array BioPharma (ARRY) got the development and commercialization rights for binimetinib and encorafenib under asset transfer agreements with Novartis (NVS).
In 2Q17, BioMarin Pharmaceuticals’ (BMRN) Aldurazyme generated revenues of around $20 million, which was a ~6% increase on a year-over-year (or YoY) basis.
To expand Xyrem’s addressable market, JAZZ has been evaluating the efficacy of Xyrem in pediatric narcolepsy patients with cataplexy and excessive sleepiness.
Price movement Deckers Outdoor (DECK) has a market cap of $1.9 billion. It rose 4.9% to close at $60.17 per share on November 11, 2016. The stock’s weekly, monthly, and year-to-date (or YTD) price movements were 15.2%, 5.7%, and 27.5%, respectively, on the same day. DECK is trading 11.7% above its 20-day moving average, 3.8% […]
Price movement Boston Beer (SAM) has a market cap of $1.9 billion. It fell 4.8% to close at $155.41 per share on October 14, 2016. The stock’s weekly, monthly, and year-to-date (or YTD) price movements were -1.3%, -5.5%, and -23.0%, respectively, on the same day. SAM is trading 0.16% above its 20-day moving average, 9.5% […]
Macao casinos’ $28-billion investment in integrated resorts will change the city’s gaming. Capacity additions should increase the number of slot tables too.
LinkedIn (LNKD) invests aggressively in Sponsored Updates, with the aim of incorporating additional functionalities and streamlining the process of targeting ads for the marketers.
There are four drugs in the pipeline targeting Duchenne muscular dystrophy. The company holds Kyndrisa, BMN044, BMN045, and BMN053 for the indication of DMD.
Kuvan, with the active ingredient sapropterin dihydrochloride, is effective in reducing blood phenylalanine levels in PKU (or phenylketonuria) patients.
The FDA advisory committee has given an unfavorable opinion to Kyndrisa. But most analysts estimate the probability of FDA approval for the drug to be about 50%.
Doug Merritt, who joined Splunk as Senior Vice President of Field Operations in 2014, will become CEO, following Godfrey Sullivan’s decision to step down.
Microsemi has made a third offer for the acquisition of PMC-Sierra, increasing the cash component. The revised offer values PMC-Sierra at $12.05 per share.
EMC was being pressured by Elliott Management, which owns a 2.2% stake in the firm, to split the company and spin off VMware (VMW). With this deal, Dell saves EMC from this pressure while agreeing to a “go-shop” clause, which gives it 60 days to seek competing offers from other potential suitors.
Following the Dell-EMC merger, EMC will go private while VMware (VMW) will continue to be independent and trade publicly. For each EMC share, shareholders will receive cash of $24.05 and $9.10 of tracking stock linked to EMC’s stake in the VMware business.
In 4Q14, JAT Capital sold its stake in Hertz Global Holdings (HTZ). The $196-million position had represented 3.2% of the fund’s third-quarter portfolio.
